An L-threonine aldolase mutant for preparing L-configuration β-p-methylsulfonylphenyl-α-hydroxymethyl-serine

By performing site-directed and combinatorial mutagenesis on BnLTA, a highly active L-threonine aldolase mutant was obtained, which solved the problem of low catalytic activity of existing enzymes and achieved efficient catalysis of D-serine and p-methylsulfonylbenzaldehyde to produce L-configuration β-hydroxy-α-amino acids, with the advantages of high conversion rate and high yield.

CN123063386APending Publication Date: 2026-11-10ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611258317.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-18
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing L-threonine aldolases exhibit low catalytic activity for D-serine and p-methylsulfonylbenzaldehyde, resulting in insufficient substrate conversion and low product yield, thus limiting the synthesis efficiency of β-hydroxy-α-amino acids.

Method used

By performing site-directed saturation mutagenesis and combinatorial mutagenesis on Bacillus niger BnLTA, highly active mutant L-threonine aldolases were obtained, specifically including the Y8S/G60N/D126S mutants. These mutants improved the catalytic performance, enabling high conversion rates and product yields in the reaction system of D-serine and p-methylsulfonylbenzaldehyde under mild conditions.

Benefits of technology

The mutant exhibits catalytic activity increased by 1.7 to 68.1 times, substrate conversion rate reaches 95.3%, and product yield reaches 90.2%, achieving efficient and environmentally friendly synthesis of β-hydroxy-α-amino acids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063386A_ABST
    Figure CN123063386A_ABST
Patent Text Reader

Abstract

This invention relates to the field of enzyme engineering technology, specifically to an L-threonine aldolase mutant for the preparation of L-configuration β-p-methylsulfonylphenyl-α-hydroxymethyl-serine. This L-threonine aldolase mutant is obtained by mutating the wild-type L-threonine aldolase with accession number WP_016204489.1. Experiments show that the catalytic activity of the mutant for D-serine is 1.7 to 68.1 times that of the wild type. The beneficial mutant provided by this invention can lay a good foundation for the industrial production of L-configuration β-hydroxy-α-amino acids.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of enzyme engineering technology, and specifically to an L-threonine aldolase mutant for preparing L-configuration β-p-methylsulfonylphenyl-α-hydroxymethyl-serine. Background Technology

[0002] β-hydroxy-α-amino acids possess both an amino acid backbone and a β-hydroxyl group, typically containing two chiral centers, and can form different stereoisomers. These compounds are important chiral intermediates in the synthesis of various drugs, pesticides, natural products, and fine chemicals, and are particularly suitable as structural units with defined configurations.

[0003] When constructing adjacent chiral centers using traditional chemical methods, chiral catalysts, protecting groups, or subsequent resolution steps are often required. Enzymatic catalysis can achieve carbon-carbon bond construction in aqueous phases or under mild conditions, thus offering potential advantages in reducing steps, controlling stereochemistry, and minimizing environmental impact.

[0004] L-threonine aldolases are a class of pyridoxal phosphate (PLP)-dependent enzymes that catalyze aldol condensation reactions between amino acid donors and aldehyde acceptors. Existing L-threonine aldolase (LTA) reactions mostly use glycine as the amino substrate; in contrast, D-serine already possesses a hydroxymethyl side chain, and its condensation with aromatic aldehydes can form β-hydroxy-α-amino acids with more complex substitution patterns.

[0005] The ability of LTAs to accept D-serine is not a universal property of this type of enzyme. Literature reports a limited number of LTAs capable of synthesizing the corresponding β-hydroxy-α-amino acids from D-serine, and the reported catalytic activity of wild-type enzymes is generally low. This low activity leads to insufficient substrate conversion, increased catalyst dosage, and limitations on reaction scale-up.

[0006] p-Methylsulfonylbenzaldehyde (MTB) contains a p-methylsulfonyl-substituted aromatic aldehyde structure and can undergo a carbon-carbon bond formation reaction with D-serine under LTA catalysis. To make this route more applicable, it is necessary to improve the catalytic performance of the enzyme in the D-serine and MTB reaction system and verify the substrate conversion and product yield in a larger reaction system.

[0007] Site-directed saturation mutagenesis can introduce different side-chain properties at selected amino acid sites, thereby altering substrate binding space, local polarity, or conformation. Combining beneficial substitutions at different sites may further improve catalytic performance. However, the combined effect cannot be inferred from single-site results and must be confirmed through experimental screening.

[0008] Therefore, there is a need in this field for [specific] sources that are clearly defined. BnLTA was used to identify modifiable sites, and single-site and combinatorial mutant libraries were established. A unified D-serine / MTB reaction system was used to screen for conversion and enzyme activity, and the catalytic performance of the selected mutants in the scale-up system was verified. Summary of the Invention

[0009] In view of this, the present invention uses Bacillus niger. Bacillus nealsonii source Bn Using LTA as the parent, site-directed saturation mutagenesis and combinatorial mutagenesis were performed at the N6, Y8, G60, and D126 sites to obtain highly active mutants, including Y8S / G60N / D126S, providing modified enzymes for the D-serine-mediated LTA aldol condensation reaction. This method boasts advantages such as simple production process, mild reaction conditions, up to 100% atom utilization, and a green and environmentally friendly production process.

[0010] The specific technical solution is as follows: In one aspect, the present invention provides an L-threonine aldolase mutant with enhanced enzyme activity, said mutant having three or fewer amino acid substitutions relative to the amino acid sequence shown in SEQ ID NO.2, said substitutions being selected from: N6A, N6C, N6D, N6E, N6F, N6G, N6H, N6I, N6M, N6P, N6R, N6S, N6T, N6V, N6W, N6Y, Y8A, Y8C, Y8E , Y8H, Y8I, Y8K, Y8L, Y8M, Y8N, Y8P, Y8Q, Y8S, Y8T, Y8V, Y8W, G60A, G60C, G60F, G60I, G60K, G6 0L, G60M, G60N, G60Q, G60R, G60S, G60T, G60V, G60W, D126A, D126C, D126E, D126F, D126G, D1 26H, D126I, D126K, D126L, D126M, D126N, D126P, D126Q, D126R, D126S, D126T, D126V, D126W; Or combinations thereof: N6W / Y8S, N6G / Y8I, N6G / Y8C, Y8S / G60N, N6S / G60N, G60N / D126S, Y8S / D126S, N6W / Y8S / D126S and Y8S / G60N / D126S.

[0011] In one aspect, the present invention provides a gene encoding the above-described L-threonine aldolase mutant.

[0012] In one aspect, the present invention provides a recombinant expression vector comprising the above-mentioned genes.

[0013] Furthermore, the recombinant expression vector is the pET-28a(+) expression vector.

[0014] In one aspect, the present invention provides a recombinant microorganism comprising the above-described gene or the above-described recombinant expression vector.

[0015] Furthermore, the recombinant microorganism is Escherichia coli BL21(DE3).

[0016] In one aspect, the present invention provides a catalyst comprising the above-mentioned L-threonine aldolase mutant or the above-mentioned recombinant microorganism; the catalyst is an enzyme preparation of the mutant, an immobilized enzyme, or a whole cell or cell lysate of the recombinant microorganism.

[0017] In another aspect, the present invention provides the application of the aforementioned L-threonine aldolase mutant, or the aforementioned recombinant microorganism, or the aforementioned catalyst in the preparation of L-configuration β-hydroxy-α-amino acids.

[0018] In one aspect, the present invention provides a method for preparing L-configuration β-hydroxy-α-amino acids, comprising: using D-serine and p-methylsulfonylbenzaldehyde as substrates, pyridoxal phosphate as a cofactor, and performing a condensation reaction using the aforementioned catalyst to generate L-configuration β-hydroxy-α-amino acids; wherein the L-configuration β-hydroxy-α-amino acid is L-configuration β-p-methylsulfonylphenyl-α-hydroxymethyl-serine.

[0019] Compared with the prior art, the present invention has the following beneficial effects: Through the Bn LTA site-directed mutagenesis and screening yielded L-threonine aldolase mutants with significantly enhanced catalytic performance, capable of effectively catalyzing the synthesis of L-configuration β-hydroxy-α-amino acids from MTB and D-serine. The catalytic activity of these mutants for D-serine was 1.7–68.1 times that of the wild type, with the optimal mutant Y8S / G60N / D126S exhibiting an enzyme activity of 4100.3 mU / L, 68.1 times that of the wild type. Using this mutant to catalyze the reaction of MTB and D-serine for 8 h, the substrate conversion rate reached 95.3%, and the product yield reached 90.2%. This invention offers advantages such as high atom economy, simple catalytic process, mild reaction conditions, and no reaction byproducts, demonstrating potential application in the synthesis of L-configuration β-hydroxy-α-amino acids. Attached Figure Description

[0020] Figure 1 The reaction equation is for the condensation of p-methylsulfonylbenzaldehyde with D-serine to L-configuration β-p-methylsulfonylphenyl-α-hydroxymethyl-serine catalyzed by L-threonine aldolase (LTA).

[0021] Figure 2The image shows the liquid chromatography analysis results of the reaction product, L-configuration β-p-methylsulfonylphenyl-α-hydroxymethyl-serine. Detailed Implementation

[0022] To enable those skilled in the art to better understand the present invention, the technical solution of the present invention will be clearly and completely described below in conjunction with specific embodiments. It should be noted that the following detailed descriptions are exemplary and only represent a part of the embodiments of the present invention, not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort should fall within the scope of protection of the present invention.

[0023] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains. The experimental materials used in the embodiments of this invention are all conventional experimental materials in the art and are commercially available. Experimental methods not specifying detailed conditions are performed according to conventional experimental methods or the operating instructions recommended by the supplier.

[0024] In this invention, the bacteria are derived from Bacillus niger ( Bacillus nealsonii L-threonine aldolase ( Bn The nucleotide sequence of the LTA encoding gene is shown in SEQ ID NO.1, with a full length of 1011 bp.

[0025] SEQ ID NO.1:

[0026] In this invention, the bacteria are derived from Bacillus niger ( Bacillus nealsonii L-threonine aldolase ( Bn The amino acid sequence of LTA is shown in SEQ ID NO.2, with a full length of 337 aa.

[0027] SEQ ID NO.2: MYSFNNDYSEGAHPRILQALVESNLQQEIGYGQDSFTNKAAEVLKTKMNSDEVDVHLLVGGTQTNLIAISAFLRPHEAAIAASTGHIFVHETGAIEATGHKVITVDAKYGKLTPSLVQSVLDEHTDEHMVKPKLVYISNSTEIGTIYSKSELEQLSQFCQINNLIFYMD GARLGSALCAKDNDLVLSDFPKLLDAFYIGGTKNGALMGEALVIKNDSLKTDFRYHIKQKGAMLAKGRLLGIQFYELFKDDLFFELAEYANKMAERLNIALAEKDYRFLTPSSTNQVFPIFSNEKITMLQKNYQFNIWEKIDKDHSAIRLVTSWATKEAEVEAFINEI.

[0028] The reagents used in the catalytic process, including D-serine, p-methylsulfonylbenzaldehyde, and pyridoxal phosphate, were all commercially available analytical grade.

[0029] This invention uses high-performance liquid chromatography (HPLC) to analyze the concentrations of substrates and products in the reaction solution and monitor the reaction process. The HPLC analysis method is as follows: the chromatographic column is a CHIRALPAK ZWIX(-) (DAICEL CO., LTD, Japan); the mobile phase is 1 L methanol, 1.9 mL formic acid, and 2.6 mL ethylenediamine; the flow rate is 0.5 mL / min; the column oven temperature is 40 ℃; and the detection wavelength is 225 nm.

[0030] Example 1: Construction of wild-type L-threonine aldolase engineered bacteria The L-threonine aldolase gene was retrieved from the NCBI database, and the L-threonine aldolase with accession number WP_016204489.1 was selected. Bn LTA), whose encoding gene has the nucleotide sequence shown in SEQ ID NO.1 and the amino acid sequence shown in SEQ ID NO.2. In this embodiment, according to BnThe LTA gene sequence was obtained using whole-genome synthesis technology after codon optimization by General Biosystems (Anhui) Co., Ltd., and then cloned into pET-28a(+). BamH I and Hind Between the III restriction sites, the corresponding recombinant plasmid was obtained and named pET28a- Bn LTA; finally, the constructed plasmid was introduced into Escherichia coli BL21(DE3) host cells to construct L-threonine aldolase engineered bacteria.

[0031] Example 2: Construction of L-threonine aldolase mutant 1. Activation of engineered bacteria and plasmid extraction engineered bacteria ( E. coli BL21(DE3), obtained in Example 1, was activated and cultured using LB medium with the following formulation: 10 g / L peptone, 5 g / L yeast extract, and 10 g / L NaCl, dissolved in deionized water and brought to a final volume. The mixture was then sterilized at 121 °C for 20 min and set aside for use. The solid medium was LB medium with 1-2% agar added.

[0032] The preserved engineered bacterial glycerol tubes were inoculated into test tubes containing 10 mL of LB medium and cultured overnight at 37 ℃ and 220 rpm. After obtaining the cultured bacterial cells, plasmids were extracted according to the instructions of the Axygen plasmid extraction kit. The obtained plasmids can be used directly for point mutagenesis or stored long-term at -20 ℃.

[0033] 2. Site-directed gene mutation Gene mutations were obtained using whole-plasmid PCR. The PCR amplification system is shown in Table 1.

[0034] Table 1. PCR amplification system reagents Dosage DNA polymerase 25 μL upstream primer 1 μL Downstream primer 1 μL plasmid template 0.5 μL <![CDATA[ddH2O]]> 22.5 μL PCR amplification program: (1) Pre-denaturation: 98 ℃ for 5 min; (2) Denaturation: 98 ℃ for 30 s, annealing: 60 ℃ for 30 s, extension: 72 ℃ for 90 s, for a total of 30 cycles; (3) Post-extension: 72 ℃ for 10 min; (4) Store at 4 ℃.

[0035] After PCR amplification, the amplification product was detected by 0.9% agarose gel electrophoresis. The results showed that the amplification product was a single band, approximately 6500 bp in size. The amplification product was purified and recovered using a DNA purification kit. The specific steps were followed according to the kit's instructions, and the primers used are shown in Table 2.

[0036] Table 2. Mutation primers for different mutants Primers sequence N6NNK_F CAGTTTCAACNNKGATTACAGTGAAGGCGC (SEQ ID NO.3) N6NNK_R ACTGTAATCMNNGTTGAAACTGTACATGGATC (SEQ ID NO.4) Y8NNK_F AACAACGATNNKAGTGAAGGCGCACATC (SEQ ID NO.5) Y8NNK_R CCTTCACTMNNATCGTTGTTGAAACTGTACATG (SEQ ID NO.6) G60NNK_F CTGGTTNNKGGTACCCAGACCAATC (SEQ ID NO.7) G60NNK_R GTACCGMNNACCAGCAGATGCACATC (SEQ ID NO.8) D126NNK_F TGAACATACCNNKGAACATATGGTGAAACCGAA (SEQ ID NO.9) D126NNK_R CATATTGTTCMNNGGTATGTTCATCCAGCAC (SEQ ID NO.10) 3. Construction of mutant engineered bacteria The purified gene fragment was digested with DpnI to remove the template, and the product was transformed into... E. coli In BL21(DE3) competent cells, the cells were plated, and single colonies were picked and cultured in LB broth. Positive transformants were identified by PCR, and the correctness of the mutation sites was verified by sequencing. After verification, sterile glycerol was added to a final concentration of 15%, and the cells were labeled and stored at -80 °C for later use.

[0037] Example 3: Activity assay of L-threonine aldolase mutant library 1. Culture of bacterial cells Liquid culture medium composition: 10 g / L peptone, 5 g / L yeast extract, 10 g / L NaCl, dissolved in deionized water and brought to a final volume, then sterilized at 121 °C for 20 min.

[0038] After activating the engineered bacteria from Examples 1 and 2 by streak plating, single colonies were inoculated into 5 mL of LB broth containing 50 μg / mL kanamycin (Kan) and cultured overnight at 37 °C with shaking. Then, 2% of the inoculum was transferred to 50 mL of fresh LB broth containing 50 μg / mL Kan and cultured at 37 °C with shaking until OD (October Expiratory Time) was reached. 600 When the concentration reaches approximately 0.8, add isopropyl-β-D-thiogalactoside (IPTG) to a final concentration of 0.5 mM, and induce culture at 18 ℃ for 18–24 h. After culture, centrifuge the culture at 4000 rpm for 10 min, discard the supernatant, collect the bacterial cells, wash the cells twice with 10 mM pH 8.0 phosphate buffer, and store at -80 ℃ for later use.

[0039] 2. Preparation of crude enzyme solution After the culture was completed, the bacterial cells collected were resuspended four times in 1 M pH 8.0 D-serine-PBS buffer and sonicated 30 times at 400W, with each sonication lasting 3 seconds and a 7-second interval. The lysate was centrifuged at 12000 rpm and 4 ℃ for 10 min to remove the precipitate. The supernatant obtained was the crude enzyme solution containing L-threonine aldolase.

[0040] 3. Enzyme activity assay according to BnThe catalytic properties of LTA were determined by measuring its enzyme activity using the ability to generate β-p-methylsulfonylphenyl-α-hydroxymethyl-serine as a standard. The enzyme activity assay consisted of a 500 μL system containing 1 M D-serine, 0.1 M p-methylsulfonylbenzaldehyde, 40 μM PLP, and 500 μL of crude enzyme solution. The reaction system was incubated at 30 °C and shaken at 700 rpm for 24 h. Multiple samples were taken, and the content of β-p-methylsulfonylphenyl-α-hydroxymethyl-serine in the system was detected by HPLC.

[0041] The test results are shown in Table 3. Compared with the wild-type enzyme, the L-threonine aldolase mutant exhibits superior and improved catalytic performance, and can catalyze the condensation of MTB and D-serine to generate β-p-methylsulfonylphenyl-α-hydroxymethyl-serine.

[0042] Table 3. Conversion rate and enzyme activity of L-threonine aldolase and its mutants Mutant (mutation site) Conversion rate (%) Enzyme activity (mU / L) WT 13.3±0.2 60.2±1.2 N6A 25.4±0.3 250.0±4.8 N6C 17.5±0.3 186.6±3.9 N6D 22.4±0.1 234.2±8.7 N6E 11.2±0.3 120.5±0.6 N6F 14.0±0.4 151.2±7.2 N6G 56.9±0.8 361.5±3.9 N6H 22.2±0.6 234.7±12.6 N6I 15.4±0.1 163.9±6.6 N6M 28.9±0.4 294.1±13.8 N6P 27.7±0.06 292.8±11.1 N6R 28.2±0.2 199.7±5.8 N6S 36.6±0.5 384.6±3.2 N6T 34.0±0.2 361.2±8.4 N6V 30.5±0.3 342.2±15.6 N6W 29.1±0.1 100.1±13.0 N6Y 21.1±0.1 109.1±1.5 Y8A 25.6±0.2 166.9±2.2 Y8C 20.2±0.6 210.3±13.3 Y8E 22.1±0.2 122.4±7.4 Y8H 22.7±0.7 134.5±9.1 Y8I 26.3±0.1 167.4±8.9 Y8K 27.5±0.6 121.4±1.7 Y8L 34.7±0.2 209.5±1.4 Y8M 33.8±0.8 144.2±2.9 Y8N 35.8±0.8 140.4±2.0 Y8P 28.9±0.2 181.3±2.8 Y8Q 34.1±0.1 149.7±4.7 Y8S 77.9±0.8 840.2±12.5 Y8T 36.9±0.7 256.7±2.4 Y8V 44.8±0.4 256.1±3.4 Y8W 39.2±0.7 200.0±4.2 G60A 49.8±0.9 199.3±3.4 G60C 41.2±0.6 422.2±6.7 G60F 40.7±0.2 110.9±9.0 G60I 37.7±0.5 200.6±3.1 G60K 38.8±0.4 188.3±2.7 G60L 50.2±0.2 243.8±6.2 G60M 38.1±0.3 188.8±1.8 G60N 53.6±0.9 576.8±5.6 G60Q 44.6±0.6 359.0±5.2 G60R 36.9±0.1 192.5±3.3 G60S 51.0±0.4 247.8±5.9 G60T 44.8±0.1 355.7±4.6 G60V 36.7±0.2 253.7±2.7 G60W 42.1±0.3 210.7±2.9 D126A 40.2±0.0 211.6±2.7 D126C 39.0±0.2 117.2±0.9 D126E 46.2±0.3 203.7±1.0 D126F 48.5±0.6 500.0±6.7 D126G 50.8±0.2 371.1±3.2 D126H 60.0±0.2 310.9±1.2 D126I 44.5±0.1 233.4±3.8 D126K 34.6±0.1 181.6±2.9 D126L 48.5±0.3 255.7±3.2 D126M 39.2±0.1 141.0±1.2 D126N 79.2±0.7 299.9±8.2 D126P 40.5±0.2 219.6±3.9 D126Q 46.7±0.1 199.6±4.8 D126R 44.2±0.1 185.2±8.9 D126S 68.9±0.8 180.8±4.2 D126T 42.1±0.4 220.8±3.2 D126V 34.5±0.3 186.3±1.0 D126W 34.7±0.2 187.6±4.9 N6W / Y8S 94.2±0.5 1490.2±10.8 N6G / Y8I 87.2±0.3 456.1±6.7 N6G / Y8C 80.1±0.5 500.0±2.5 Y8S / G60N 81.5±0.4 1500.4±9.0 N6S / G60N 79.4±0.1 310.2±2.2 G60N / D126S 98.2±0.4 840.4±3.6 Y8S / D126S 93.6±0.2 1012.2±9.2 N6W / Y8S / D126S 94.2±0.5 2300.4±8.2 Y8S / G60N / D126S 95.2±0.8 4100.3±12.2 Example 4: Application of the Y8S / G60N / D126S mutant in the production of L-configuration β-hydroxy-α-amino acids This embodiment utilizes basic raw materials such as MTB and D-serine to efficiently catalyze the synthesis of L-configuration β-hydroxy-α-amino acids with the addition of PLP cofactor.

[0043] The mutant Y8S / G60N / D126S engineered bacteria were inoculated into seed culture medium containing kanamycin and cultured overnight on a shaker at 37 ℃ and 220 rpm to obtain the seed culture; then, it was transferred to 4 L of medium at a 2% inoculation rate. When OD 600 When the concentration reaches 0.8, 0.5 mM IPTG is added for induction, and the culture temperature is lowered to 18 ℃. The culture is induced for 18~24 h. Finally, the bacterial culture is centrifuged at 4000 rpm and 4 ℃ for 30 min to collect the bacterial cells. After removing the supernatant, the recombinant bacterial sludge is obtained.

[0044] The bacterial sludge was resuspended in 1 L PBS (pH 8.0) and homogenized. 0.1 M MTB, 0.5 M D-serine, and 0.5 mM PLP were added. The reaction mixture was placed in a 30 ℃ water bath and reacted at 300–500 rpm for 8 h. The substrate conversion rate of MTB was 95.3%, and the product yield was 90.2%.

Claims

1. A mutant of L-threonine aldolase with enhanced enzyme activity, characterized in that, The mutant has three or fewer amino acid substitutions relative to the amino acid sequence shown in SEQ ID NO. 2, wherein the substitutions are selected from: N6A, N6C, N6D, N6E, N6F, N6G, N6H, N6I, N6M, N6P, N6R, N6S, N6T, N6V, N6W, N6Y, Y8A, Y8C, Y8E , Y8H, Y8I, Y8K, Y8L, Y8M, Y8N, Y8P, Y8Q, Y8S, Y8T, Y8V, Y8W, G60A, G60C, G60F, G60I, G60K, G6 0L, G60M, G60N, G60Q, G60R, G60S, G60T, G60V, G60W, D126A, D126C, D126E, D126F, D126G, D1 26H, D126I, D126K, D126L, D126M, D126N, D126P, D126Q, D126R, D126S, D126T, D126V, D126W; Or combinations thereof: N6W / Y8S, N6G / Y8I, N6G / Y8C, Y8S / G60N, N6S / G60N, G60N / D126S, Y8S / D126S, N6W / Y8S / D126S and Y8S / G60N / D126S.

2. A gene encoding the L-threonine aldolase mutant as described in claim 1.

3. A recombinant expression vector comprising the gene as described in claim 2.

4. The recombinant vector according to claim 3, characterized in that, The recombinant expression vector is the pET-28a(+) expression vector.

5. A recombinant microorganism, characterized in that, The recombinant microorganism comprises the gene of claim 2 or the recombinant expression vector of claim 3 or 4.

6. The recombinant microorganism according to claim 5, characterized in that, The recombinant microorganism is Escherichia coli BL21(DE3).

7. A catalyst, characterized in that, The catalyst comprises the L-threonine aldolase mutant of claim 1 or the recombinant microorganism of claim 4; the catalyst is an enzyme preparation of the mutant, an immobilized enzyme, or a whole cell or cell lysate of the recombinant microorganism.

8. The use of an L-threonine aldolase mutant as described in claim 1, or a recombinant microorganism as described in claim 5 or 6, or a catalyst as described in claim 7 in the preparation of L-configuration β-hydroxy-α-amino acids.

9. A method for preparing L-configuration β-hydroxy-α-amino acids, characterized in that, Using D-serine and p-methylsulfonylbenzaldehyde as substrates and pyridoxal phosphate as a cofactor, a condensation reaction is carried out using the catalyst described in claim 7 to generate an L-configuration β-hydroxy-α-amino acid; wherein the L-configuration β-hydroxy-α-amino acid is L-configuration β-p-methylsulfonylphenyl-α-hydroxymethyl-serine.